Analysts lower price targets for Thermo Fisher (TMO)

Thermo Fisher's earnings beat spurs mixed analyst sentiment, driving price target revisions.

Thermo Fisher Scientific (TMO) reported first-quarter results above estimates on April 23, with growth in lab products and biopharma services offsetting softness in other segments. Despite this, TD Cowen lowered its price target from $683 to $625 on April 13, while maintaining a 'Buy' rating, indicating mixed analyst sentiment.

Healthcare and life sciences stocks may face valuation repricing as analysts reassess growth prospects.

Thermo Fisher's mixed earnings reception could signal a reassessment of growth prospects in the healthcare and life sciences sectors. Investors may reevaluate valuations, potentially impacting other companies in these spaces, such as Abbott Laboratories (ABT) and Illumina (ILMN).

Upcoming earnings and analyst revisions will dictate the narrative's evolution.

Investors should watch Thermo Fisher's second-quarter earnings, due in late July, for further clarity on the company's growth trajectory. Additionally, any changes in analyst price targets and ratings will provide insight into the broader market's sentiment towards the healthcare and life sciences sectors.